Search

Displaying results 2561 - 2570 of 7706 in total
  1. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.

  2. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

  3. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA cha...

  4. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative ...

    Mixtures: FLOBACT - D, FLOBACT - D
  5. Drug

    Flumethasone

    go.drugbank.com/drugs/DB00663
    ApprovedVet approved

    Flumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of applicati...

  6. Target

    Vascular endothelial growth factor receptor

    go.drugbank.com/bio_entities/BE0010227
    TargetHumans

    Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage fun...

    Synonyms: FRT, Tyrosine-protein kinase FRT
  7. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286]. … VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287].

  8. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  9. Drug

    Thonzonium

    go.drugbank.com/drugs/DB09552
    Approved

    It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone. … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication.

  10. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. … discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study.